homepage-top-section

Data from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials support these approvals. They cover the use of Enhertu in both the neoadjuvant and adjuvant treatment settings for adult

Affecting adults and children, this rare, progressive, genetic disorder impacts both bone and muscle health due to the body’s inability to retain sufficient phosphorus, a mineral essential for

The offer was approved by Assertio’s Board of Directors, following a revised merger agreement process and is considered a “superior proposal” compared to the previous agreement with Garda

The approval is intended for adults with PsA who have had inadequate response or intolerance to previous disease-modifying antirheumatic drug (DMARD) therapy. Sotyktu can be used alone or

The acquisition has been approved unanimously by both companies’ boards of directors, with the transaction expected to close in the third quarter of 2026. Angelini Pharma will purchase

Oruka has licensed the Halozyme technology for use with its lead programme, ORKA-001, which is in development to treat psoriasis and related inflammatory conditions, and up to one

Following a successful tender offer and subsequent merger, the companies announced the completion of the transaction, making Terns a wholly owned subsidiary of MSD. The US Food and

The financing includes a $43m extension led by 8VC, with participation from existing investors BioAdvance, Benjamin Franklin Technology Partners, DCVC Bio, Gaingels, Hatch BioFund and Modi Ventures. New

The Ozempic oral pill, approved by the Food and Drug Administration (FDA), offers an option for adults with type 2 diabetes to manage blood sugar and cardiovascular risk